N30 Pharma Raises $30M
Boulder-based N30 Pharma, a firm developing treatments for respiratory, cardiovascular, and inflammatory diseases, announced today that it has raised $10M in a new financing round. According to the firm, it is adding Dr. Howard Furst of Deerfield Management to its board of directors along with the new funding. N30 Pahrma's drugs are being applied to such diseases as cystic fibrosis. The firm said the funding will help move its first drug, N6022, into human testing, as well as go towards development of other new drugs.
posted on Tuesday, May 11, 2010 (Link to more information)
Related companies:
N30 Pharma
Related stories:
> N30 Pharma In Deal With NitroMed
> N30 Expands Board
> N30 Pharma Finds $30M More
> N30 Pharma Gets Funding
> miRagen Therapeutics Raises $40M, Goes Public In Reverse Merger
Techrockies.com Home